Literature DB >> 12171943

From hyperplasia to T cell lymphoma.

N Cerf-Bensussan1, N Brousse, C Cellier.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12171943      PMCID: PMC1773362          DOI: 10.1136/gut.51.3.304

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  11 in total

1.  Mortality in patients with coeliac disease and their relatives: a cohort study.

Authors:  G Corrao; G R Corazza; V Bagnardi; G Brusco; C Ciacci; M Cottone; C Sategna Guidetti; P Usai; P Cesari; M A Pelli; S Loperfido; U Volta; A Calabró; M Certo
Journal:  Lancet       Date:  2001-08-04       Impact factor: 79.321

2.  Molecular analysis of T-cell clonality in ulcerative jejunitis and enteropathy-associated T-cell lymphoma.

Authors:  M Ashton-Key; T C Diss; L Pan; M Q Du; P G Isaacson
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

3.  Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center.

Authors:  J Gale; P D Simmonds; G M Mead; J W Sweetenham; D H Wright
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

4.  Abnormal intestinal intraepithelial lymphocytes in refractory sprue.

Authors:  C Cellier; N Patey; L Mauvieux; B Jabri; E Delabesse; J P Cervoni; M L Burtin; D Guy-Grand; Y Bouhnik; R Modigliani; J P Barbier; E Macintyre; N Brousse; N Cerf-Bensussan
Journal:  Gastroenterology       Date:  1998-03       Impact factor: 22.682

5.  Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group.

Authors:  C Cellier; E Delabesse; C Helmer; N Patey; C Matuchansky; B Jabri; E Macintyre; N Cerf-Bensussan; N Brousse
Journal:  Lancet       Date:  2000-07-15       Impact factor: 79.321

6.  Frequency of clonal intraepithelial T lymphocyte proliferations in enteropathy-type intestinal T cell lymphoma, coeliac disease, and refractory sprue.

Authors:  S Daum; D Weiss; M Hummel; R Ullrich; W Heise; H Stein; E O Riecken; H D Foss
Journal:  Gut       Date:  2001-12       Impact factor: 23.059

7.  Enteropathy-associated T cell lymphoma (malignant histiocytosis of the intestine) is recognized by a monoclonal antibody (HML-1) that defines a membrane molecule on human mucosal lymphocytes.

Authors:  J Spencer; N Cerf-Bensussan; A Jarry; N Brousse; D Guy-Grand; A S Krajewski; P G Isaacson
Journal:  Am J Pathol       Date:  1988-07       Impact factor: 4.307

8.  Heterogeneity of intraepithelial lymphocytes in refractory sprue: potential implications of CD30 expression.

Authors:  I N Farstad; F-E Johansen; L Vlatkovic; J Jahnsen; H Scott; O Fausa; A Bjørneklett; P Brandtzaeg; T S Halstensen
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

9.  Are complicated forms of celiac disease cryptic T-cell lymphomas?

Authors:  F Carbonnel; L Grollet-Bioul; J C Brouet; M F Teilhac; J Cosnes; R Angonin; M Deschaseaux; F P Châtelet; J P Gendre; F Sigaux
Journal:  Blood       Date:  1998-11-15       Impact factor: 22.113

10.  Study of the immunohistochemistry and T cell clonality of enteropathy-associated T cell lymphoma.

Authors:  A Murray; E C Cuevas; D B Jones; D H Wright
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

View more
  3 in total

Review 1.  CD4+ T-cell lymphoproliferative disorder of the gut clinically mimicking celiac sprue.

Authors:  Jaroslav Zivny; Barbara F Banner; Sanjay Agrawal; German Pihan; Graham F Barnard
Journal:  Dig Dis Sci       Date:  2004-04       Impact factor: 3.199

Review 2.  Coeliac disease: an update for pathologists.

Authors:  B C Dickson; C J Streutker; R Chetty
Journal:  J Clin Pathol       Date:  2006-10       Impact factor: 3.411

3.  Refractory coeliac sprue is a diffuse gastrointestinal disease.

Authors:  V Verkarre; V Asnafi; T Lecomte; N Patey Mariaud-de Serre; M Leborgne; E Grosdidier; C Le Bihan; E Macintyre; C Cellier; N Cerf-Bensussan; N Brousse
Journal:  Gut       Date:  2003-02       Impact factor: 23.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.